Global Severe Combined Immunodeficiency (SCID) Diagnosis Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Severe Combined Immunodeficiency (SCID) Diagnosis market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses.

The global severe combined immunodeficiency (SCID) diagnosis market refers to the market for diagnostic tests used to identify and diagnose infants with SCID, a rare genetic disorder that affects the immune system. SCID is characterized by a severe deficiency in both T cells and B cells, which are crucial for the body’s immune response. Infants with SCID are highly susceptible to severe infections and require early diagnosis and treatment.

The market for SCID diagnosis includes various laboratory-based tests and screening programs. Laboratory-based tests typically involve analyzing blood samples to assess the presence and function of immune cells. Commonly used tests include flow cytometry, T-cell receptor excision circle (TREC) analysis, and next-generation sequencing (NGS) methods to detect gene mutations associated with SCID. Additionally, newborn screening programs using dried blood spot samples have also been implemented in some regions to identify infants with SCID early on.

The global SCID diagnosis market is driven by several factors. One of the primary drivers is the increasing awareness and understanding of SCID among healthcare professionals and the general population. As a result, more infants are being tested for SCID, leading to earlier detection and prompt treatment initiation. Additionally, advancements in genetic testing technologies, such as NGS, have improved the accuracy and efficiency of SCID diagnosis.

Furthermore, government initiatives and newborn screening programs in various countries have contributed to the growth of the SCID diagnosis market. These programs aim to identify infants with SCID shortly after birth, allowing for early intervention and improved outcomes. For example, the implementation of SCID newborn screening programs in several U.S. states has significantly increased the detection of affected infants and facilitated early treatment.

Geographically, North America currently dominates the global SCID diagnosis market. This is primarily due to the higher prevalence of SCID in certain populations, well-established healthcare infrastructure, and the implementation of newborn screening programs. Europe is also a significant market, while other regions, such as Asia-Pacific and Latin America, are expected to witness growth as awareness and healthcare infrastructure continue to improve.

Key players in the global SCID diagnosis market include diagnostic laboratories, healthcare providers, and companies specializing in genetic testing. These companies focus on developing innovative testing methods, improving existing diagnostic tools, and collaborating with healthcare professionals and researchers to advance SCID diagnosis and management.

Overall, the global SCID diagnosis market is expected to witness substantial growth in the coming years, driven by factors such as increased awareness, advancements in genetic testing technologies, and the implementation of newborn screening programs. Early diagnosis and timely intervention are crucial for improving outcomes and quality of life for infants with SCID, emphasizing the importance of continued efforts in SCID diagnosis and management.

This report is a detailed and comprehensive analysis for global Severe Combined Immunodeficiency (SCID) Diagnosis market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Severe Combined Immunodeficiency (SCID) Diagnosis market size and forecasts, in consumption value ($ Million), 2020-2031

Global Severe Combined Immunodeficiency (SCID) Diagnosis market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Severe Combined Immunodeficiency (SCID) Diagnosis market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Severe Combined Immunodeficiency (SCID) Diagnosis market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Severe Combined Immunodeficiency (SCID) Diagnosis

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Severe Combined Immunodeficiency (SCID) Diagnosis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ARCHIMEDlife, PerkinElmer, Health Research, Inc, Winfertility, Portea Medical, LaCAR MDX Technologies, Labsystems Diagnostics Oy, Devyser Diagnostics, Revcovi, Leadiant Biosciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Severe Combined Immunodeficiency (SCID) Diagnosis market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

TREC Test

Complete Blood Count (CBC)

Genetic Test

Biochemical Test

Others

Market segment by Application

Hospital

Outpatient Center

Diagnostic and Research Laboratories

Others

Market segment by players, this report covers

ARCHIMEDlife

PerkinElmer

Health Research, Inc

Winfertility

Portea Medical

LaCAR MDX Technologies

Labsystems Diagnostics Oy

Devyser Diagnostics

Revcovi

Leadiant Biosciences

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Severe Combined Immunodeficiency (SCID) Diagnosis product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Severe Combined Immunodeficiency (SCID) Diagnosis, with revenue, gross margin, and global market share of Severe Combined Immunodeficiency (SCID) Diagnosis from 2020 to 2025.

Chapter 3, the Severe Combined Immunodeficiency (SCID) Diagnosis competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Severe Combined Immunodeficiency (SCID) Diagnosis market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Severe Combined Immunodeficiency (SCID) Diagnosis.

Chapter 13, to describe Severe Combined Immunodeficiency (SCID) Diagnosis research findings and conclusion.